Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 69 articles:
HTML format



Single Articles


    January 2022
  1. FAHRMANN JF, Marsh T, Irajizad E, Patel N, et al
    Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
    J Clin Oncol. 2022 Jan 7:JCO2101460. doi: 10.1200/JCO.21.01460.
    PubMed     Abstract available


  2. DAI W, Feng W, Zhang Y, Wang XS, et al
    Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial.
    J Clin Oncol. 2022 Jan 7:JCO2101344. doi: 10.1200/JCO.21.01344.
    PubMed     Abstract available


  3. PASSARO A, Brahmer J, Antonia S, Mok T, et al
    Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.
    J Clin Oncol. 2022 Jan 5:JCO2101845. doi: 10.1200/JCO.21.01845.
    PubMed     Abstract available


  4. CHAFT JE, Shyr Y, Sepesi B, Forde PM, et al
    Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101589. doi: 10.1200/JCO.21.01589.
    PubMed     Abstract available


  5. DONINGTON J, Schumacher L, Yanagawa J
    Surgical Issues for Operable Early-Stage Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101592. doi: 10.1200/JCO.21.01592.
    PubMed     Abstract available


  6. TSUI DCC, Camidge DR, Rusthoven CG
    Managing Central Nervous System Spread of Lung Cancer: The State of the Art.
    J Clin Oncol. 2022 Jan 5:JCO2101715. doi: 10.1200/JCO.21.01715.
    PubMed     Abstract available


  7. PELLINI B, Chaudhuri AA
    Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
    J Clin Oncol. 2022 Jan 5:JCO2101929. doi: 10.1200/JCO.21.01929.
    PubMed     Abstract available


  8. BOGART JA, Waqar SN, Mix MD
    Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101639. doi: 10.1200/JCO.21.01639.
    PubMed     Abstract available


  9. TEMEL JS, Petrillo LA, Greer JA
    Patient-Centered Palliative Care for Patients With Advanced Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101710. doi: 10.1200/JCO.21.01710.
    PubMed     Abstract available


  10. HIGGINS KA, Puri S, Gray JE
    Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101707. doi: 10.1200/JCO.21.01707.
    PubMed     Abstract available


  11. LEVY A, Mercier O, Le Pechoux C
    Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101774. doi: 10.1200/JCO.21.01774.
    PubMed     Abstract available


  12. ZUGAZAGOITIA J, Paz-Ares L
    Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.
    J Clin Oncol. 2022 Jan 5:JCO2101881. doi: 10.1200/JCO.21.01881.
    PubMed     Abstract available


  13. DALY ME
    Inoperable Early-Stage Non-Small-Cell Lung Cancer: Stereotactic Ablative Radiotherapy and Rationale for Systemic Therapy.
    J Clin Oncol. 2022 Jan 5:JCO2101611. doi: 10.1200/JCO.21.01611.
    PubMed     Abstract available


  14. RECK M, Remon J, Hellmann MD
    First-Line Immunotherapy for Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101497. doi: 10.1200/JCO.21.01497.
    PubMed     Abstract available


  15. TAN AC, Tan DSW
    Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
    J Clin Oncol. 2022 Jan 5:JCO2101626. doi: 10.1200/JCO.21.01626.
    PubMed     Abstract available


  16. JASPER K, Stiles B, McDonald F, Palma DA, et al
    Practical Management of Oligometastatic Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101719. doi: 10.1200/JCO.21.01719.
    PubMed     Abstract available


    December 2021
  17. DALY ME, Singh N, Ismaila N, Antonoff MB, et al
    Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
    J Clin Oncol. 2021 Dec 22:JCO2102528. doi: 10.1200/JCO.21.02528.
    PubMed     Abstract available


    November 2021
  18. LE X, Cornelissen R, Garassino M, Clarke JM, et al
    Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.
    J Clin Oncol. 2021 Nov 29:JCO2101323. doi: 10.1200/JCO.21.01323.
    PubMed     Abstract available


  19. DEVARAKONDA S, Li Y, Martins Rodrigues F, Sankararaman S, et al
    Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
    J Clin Oncol. 2021;39:3747-3758.
    PubMed     Abstract available


  20. LIU SY, Zhang JT, Wu YL
    What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Nov 18:JCO2102443. doi: 10.1200/JCO.21.02443.
    PubMed    


  21. TADA H, Mitsudomi T, Misumi T, Sugio K, et al
    Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT).
    J Clin Oncol. 2021 Nov 2:JCO2101729. doi: 10.1200/JCO.21.01729.
    PubMed     Abstract available


  22. SOULIERES D, Gelmon KA
    Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?
    J Clin Oncol. 2021;39:3427-3429.
    PubMed    


    October 2021
  23. BROWN PD, Parsons MW, Rusthoven CG, Gondi V, et al
    Hippocampal Avoidance Prophylactic Cranial Irradiation: A New Standard of Care?
    J Clin Oncol. 2021;39:3093-3096.
    PubMed    


    September 2021
  24. ELAMIN YY, Robichaux JP, Carter BW, Altan M, et al
    Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.
    J Clin Oncol. 2021 Sep 22:JCO2101113. doi: 10.1200/JCO.21.01113.
    PubMed     Abstract available


  25. DRILON A, Duruisseaux M, Han JY, Ito M, et al
    Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
    J Clin Oncol. 2021;39:2791-2802.
    PubMed     Abstract available


    August 2021
  26. RAMALINGAM SS, Novello S, Guclu SZ, Bentsion D, et al
    Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
    J Clin Oncol. 2021 Aug 26:JCO2003318. doi: 10.1200/JCO.20.03318.
    PubMed     Abstract available


  27. RODRIGUEZ DE DIOS N, Counago F, Murcia-Mejia M, Rico-Oses M, et al
    Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study.
    J Clin Oncol. 2021 Aug 11:JCO2100639. doi: 10.1200/JCO.21.00639.
    PubMed     Abstract available


  28. PARK K, Haura EB, Leighl NB, Mitchell P, et al
    Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
    J Clin Oncol. 2021 Aug 2:JCO2100662. doi: 10.1200/JCO.21.00662.
    PubMed     Abstract available


  29. SHU CA, Cascone T
    What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Aug 2:JCO2101446. doi: 10.1200/JCO.21.01446.
    PubMed    


    July 2021
  30. ROTHSCHILD SI, Zippelius A, Eboulet EI, Savic Prince S, et al
    SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    J Clin Oncol. 2021 Jul 12:JCO2100276. doi: 10.1200/JCO.21.00276.
    PubMed     Abstract available


    June 2021
  31. REMON J, Hendriks LEL, Besse B
    Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Jun 8:JCO2100760. doi: 10.1200/JCO.21.00760.
    PubMed    


  32. PASSIGLIA F, Cinquini M, Bertolaccini L, Del Re M, et al
    Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2021 Jun 2:JCO2002574. doi: 10.1200/JCO.20.02574.
    PubMed     Abstract available


    May 2021
  33. GILLESSEN S, Sauve N, Collette L, Daugaard G, et al
    Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
    J Clin Oncol. 2021;39:1563-1574.
    PubMed     Abstract available


    April 2021
  34. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50.
    J Clin Oncol. 2021 Apr 19:JCO2100174. doi: 10.1200/JCO.21.00174.
    PubMed     Abstract available


    March 2021
  35. OWONIKOKO TK, Park K, Govindan R, Ready N, et al
    Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
    J Clin Oncol. 2021 Mar 8:JCO2002212. doi: 10.1200/JCO.20.02212.
    PubMed     Abstract available


  36. DERKS JL, Speel EM, Dingemans AC
    Adjuvant Chemotherapy in Patients With Stage I-IIIA Large-Cell Neuroendocrine Carcinoma: Should a Different Approach Be Applied Than for Small-Cell Lung Cancer?
    J Clin Oncol. 2021 Mar 4:JCO2003598. doi: 10.1200/JCO.20.03598.
    PubMed    


  37. DZIADZIUSZKO R, Krebs MG, De Braud F, Siena S, et al
    Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Mar 1:JCO2003025. doi: 10.1200/JCO.20.03025.
    PubMed     Abstract available


  38. WAQAR SN, Govindan R
    Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism.
    J Clin Oncol. 2021;39:697-700.
    PubMed    


  39. ZHONG WZ, Wang Q, Mao WM, Xu ST, et al
    Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
    J Clin Oncol. 2021;39:713-722.
    PubMed     Abstract available


    February 2021
  40. HANNA NH, Robinson AG, Temin S, Baker S Jr, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
    J Clin Oncol. 2021 Feb 16:JCO2003570. doi: 10.1200/JCO.20.03570.
    PubMed     Abstract available


  41. EWER MS, Tekumalla SH, Walding A, Atuah KN, et al
    Cardiac Safety of Osimertinib: A Review of Data.
    J Clin Oncol. 2021;39:328-337.
    PubMed     Abstract available


    January 2021
  42. BOYER M, Sendur MAN, Rodriguez-Abreu D, Park K, et al
    Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
    J Clin Oncol. 2021 Jan 29:JCO2003579. doi: 10.1200/JCO.20.03579.
    PubMed     Abstract available


  43. DALY ME, Ismaila N, Decker RH, Higgins K, et al
    Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline.
    J Clin Oncol. 2021 Jan 27:JCO2003364. doi: 10.1200/JCO.20.03364.
    PubMed     Abstract available


  44. GYAWALI B, West HJ
    Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.
    J Clin Oncol. 2021;39:175-177.
    PubMed    


  45. BORGHAEI H, Gettinger S, Vokes EE, Chow LQM, et al
    Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Jan 15:JCO2001605. doi: 10.1200/JCO.20.01605.
    PubMed     Abstract available


  46. LIU SV, Reck M, Mansfield AS, Mok T, et al
    Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    J Clin Oncol. 2021 Jan 13:JCO2001055. doi: 10.1200/JCO.20.01055.
    PubMed     Abstract available


    December 2020
  47. KENMOTSU H, Niho S, Tsuboi M, Wakabayashi M, et al
    Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206.
    J Clin Oncol. 2020;38:4292-4301.
    PubMed     Abstract available


  48. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
    Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
    J Clin Oncol. 2020;38:4055-4063.
    PubMed     Abstract available


    November 2020
  49. GARASSINO MC, Besse B, Torri V
    To Continue or Not to Continue? That Is the Question.
    J Clin Oncol. 2020;38:3830-3832.
    PubMed    


  50. LAU YM, Mok TSK
    The More, The Better?
    J Clin Oncol. 2020;38:3581-3583.
    PubMed    


  51. ANG E
    Four Women, One Evening.
    J Clin Oncol. 2020;38:3716-3718.
    PubMed    


    October 2020
  52. BURNS TF, Borghaei H, Ramalingam SS, Mok TS, et al
    Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.
    J Clin Oncol. 2020 Oct 26:JCO2000744. doi: 10.1200/JCO.20.00744.
    PubMed    


  53. OSAROGIAGBON RU
    Volume-Based Care Regionalization: Pitfalls and Challenges.
    J Clin Oncol. 2020;38:3465-3467.
    PubMed    


  54. GOLDBERG SB, Redman MW, Lilenbaum R, Politi K, et al
    Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.
    J Clin Oncol. 2020 Oct 6:JCO2001149. doi: 10.1200/JCO.20.01149.
    PubMed     Abstract available


    September 2020
  55. WATERHOUSE DM, Garon EB, Chandler J, McCleod M, et al
    Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
    J Clin Oncol. 2020 Sep 10:JCO2000131. doi: 10.1200/JCO.20.00131.
    PubMed     Abstract available


    August 2020
  56. ZHOU C, Li X, Wang Q, Gao G, et al
    Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.
    J Clin Oncol. 2020;38:2753-2761.
    PubMed     Abstract available


  57. CAMIDGE DR, Kim HR, Ahn MJ, Yang JCH, et al
    Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
    J Clin Oncol. 2020 Aug 11:JCO2000505. doi: 10.1200/JCO.20.00505.
    PubMed     Abstract available


  58. RUSTHOVEN CG, Camidge DR, Robin TP, Brown PD, et al
    Radiosurgery for Small-Cell Brain Metastases: Challenging the Last Bastion of Preferential Whole-Brain Radiotherapy Delivery.
    J Clin Oncol. 2020 Aug 10:JCO2001823. doi: 10.1200/JCO.20.01823.
    PubMed    


  59. FARJAH F, Grau-Sepulveda MV, Gaissert H, Block M, et al
    Volume Pledge is Not Associated with Better Short-Term Outcomes After Lung Cancer Resection.
    J Clin Oncol. 2020 Aug 7:JCO2000329. doi: 10.1200/JCO.20.00329.
    PubMed     Abstract available


    May 2020
  60. RUDIN CM, Awad MM, Navarro A, Gottfried M, et al
    Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
    J Clin Oncol. 2020 May 29:JCO2000793. doi: 10.1200/JCO.20.00793.
    PubMed     Abstract available


  61. RECK M, Wehler T, Orlandi F, Nogami N, et al
    Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 May 27:JCO1903158. doi: 10.1200/JCO.19.03158.
    PubMed     Abstract available


  62. KENMOTSU H, Yamamoto N, Yamanaka T, Yoshiya K, et al
    Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 May 14:JCO1902674. doi: 10.1200/JCO.19.02674.
    PubMed     Abstract available


  63. LEVY EB, Fiel MI, Hamilton SR, Kleiner DE, et al
    State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach.
    J Clin Oncol. 2020;38:1633-1640.
    PubMed     Abstract available


    March 2020
  64. NORONHA V, Patil VM, Joshi A, Menon N, et al
    Reply to T. Tanaka et al and F. Liang.
    J Clin Oncol. 2020;38:844-846.
    PubMed    


  65. LIANG F
    Contradiction Between Stated Statistical Analysis Method and Displayed Survival Curves.
    J Clin Oncol. 2020;38:844.
    PubMed    


  66. RAMALINGAM SS, Dahlberg SE
    Reply to N. Hanna et al and L. Xie et al.
    J Clin Oncol. 2020;38:771-772.
    PubMed    


  67. HANNA N, Jalal S
    The Case for Maintenance Pemetrexed Plus Bevacizumab.
    J Clin Oncol. 2020;38:770-771.
    PubMed    


    January 2020
  68. WU YL, Zhong WZ, Yan HH
    Reply to A. Tateishi et al.
    J Clin Oncol. 2020;38:286-287.
    PubMed    


  69. TATEISHI A, Ishiki H, Kubo E, Satomi E, et al
    EMERGING-CTONG 1103: For Achieving High-Quality Evidence in a Randomized Phase II Trial.
    J Clin Oncol. 2020;38:285-286.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: